ClinicalTrials.gg
RecruitingNCT07831681ICPAUpdated Sep 21, 2026

The Impact of a Collaborative Therapeutic Game in the Management of Psychiatric Symptoms in Adolescents

An observational study in Teenager, Psychiatric Symptoms and Psychiatric Condition, sponsored by Hospital Center Guillaume Régnier. Recruiting at 1 site in France. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by Hospital Center Guillaume Régnier · Observational

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 8 months later.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
16
Ages
12 Years to 17 Years
Sex
All
01

Study summary

When faced with psychiatric symptoms-which are characterized, in particular, by a unique perception of one's environment, the intentions of others, or events- the investigators now know that early intervention is crucial. For adults, there is a therapeutic tool in the form of a collaborative game that helps patients better understand and cope with these symptoms. A version of this game adapted for adolescents has been created: "L'océan des possibles" in French which is translated in English in "The Ocean of possibilities" (that term will be used throughout the rest of the protocol). It is used as part of a support group at the Guillaume Regnier Hospital Center.

The objective of the study is to examine in detail the impact of this game on psychiatric symptoms and patients' perceptions of those symptoms by comparing it with the impact of other types of treatment. To this end, during follow-up interviews regarding the proposed treatments, the standard assessment interview will be supplemented with additional questionnaires. The investigators plan to include 16 adolescents, aged 12 to 17, with 8 in the treatment group using the game and 8 receiving another type of treatment.

The patients will receive care tailored to their needs from the investigators' healthcare teams.

The patients participation in this study will last 1 year and will involve:

  • an enrollment visit
  • 2 scheduled follow-up visits (3 months and 6 months after the end of treatment) These visits will take place during the routine follow-up appointments held just before the start of treatment, and 3 months and 6 months after the end of treatment. Additional assessments, consisting of questionnaires and standardized scales, will be conducted to analyze The patients' symptoms, their awareness of their difficulties ("insight"), their executive functioning, and their social and interpersonal skills in greater detail.

The pre-treatment assessment should take about 1 hour and 20 minutes, and the following two assessments about 1 hour and 45 minutes each. The duration of these assessments may be adjusted, with the option to complete part of the questionnaires on their own after the interview.

02

Conditions studied

  • Teenager
  • Psychiatric Symptoms
  • Psychiatric Condition

Keywords

  • collaborative and therapeutic game
  • psychiatric symptoms
  • teenager
  • management of psychiatric symptoms
03

In context

Lead sponsor

Hospital Center Guillaume Régnier is the lead sponsor of 8 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Teenagers with psychotic symptoms that are treated in the child and adolescent psychiatry clinic.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Teenager from 12 to 17 receiving outpatient care in childrens' and teenagers' psychiatrie unit
  • Patients with psychotic symptoms (delusions, hallucinations) and thought rigidity assessed using scales (SIPS, K-SADS, SDQ)
  • A patient enrolled in or eligible for a social security program
  • Patients and parents who have received informed information about the study and have signed a consent form to participate in the study

Exclusion criteria

Exclusion Criteria:

- Patients with a previous diagnosis of Autism Spectrum Disorder

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
16 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group "The ocean of possibilities"

    Group that will play the collaborative and thepaeutic game

    Behavioral: Playing a collaborative and therapeutic game

  • Control group

    Group that will not be playing the collaborative and thepaeutic game

Interventions

  • BehavioralPlaying a collaborative and therapeutic game

    Upon inclusion, the patient will be evaluated based on the following assessments : CAPS, PDI-21 and LSHS, Ment-S, MCQ-30, R-CMAS, NEPSY-II, BRIEF, EASE and Achim's theory of mind tests. The patient will be apart of a group that will play the collaborative therapeutic game for 12 to 15 weeks with 1 game per week. 3 months after and 6 months after the patient will be evaluated based on the following assessments : CAPS, PDI-21 and LSHS, Ment-S, MCQ-30, R-CMAS, NEPSY-II, BRIEF, EASE and Achim's theory of mind tests.

06

What researchers measure

Primary outcomes

  1. Measure the impact of the collaborative therapeutic game "The Ocean of possibilities" on patients' Hallucinatory Experiences

    The patient will be assessed using the Launay Slade Hallucinations Scale (LSHS) before intervention, 3 months (more or less 15 days) after and 6 months (more or less 15 days) after the end of the intervention. Each item is scored on a scale of 0 to 4. The overall score ranges from 0 to 48. A high score indicates a greater predisposition to hallucinatory experiences.

    Time frame: From enrollment until last assessment : 1 year

  2. Measure the impact of the collaborative therapeutic game "The Ocean of possibilities" on patients' metacognition.

    The patient will be assessed using the Short french Meta-Cognitions Questionnaire (MCQ-30) before intervention, 3 months (more or less 15 days) after and 6 months (more or less 15 days) after the end of the intervention. Each item is scored on a scale of 1 to 4.The overall score ranges from 30 to 120 points.- The higher the score, the more rigid and pathogenic the metacognitive processes are considered to be.

    Time frame: From enrollment until last assessment : 1 year

  3. Measure the impact of the collaborative therapeutic game "The Ocean of possibilities" on patients' unusual perceptions

    The patient will be assessed using the Cardiff Anomalous Perceptions Scale (CAPS) before intervention, 3 months (more or less 15 days) after and 6 months (more or less 15 days) after the end of the intervention.Each item is scored on a binary scale (0 = No / 1 = Yes). The overall score ranges from 0 to 32.The higher the score, the more severe and prevalent the participant's abnormal perceptual experiences and hallucinations are.

    Time frame: From enrollment until last assessment : 1 year

  4. Measure the impact of the collaborative therapeutic game "The Ocean of possibilities" on patients' propensity for delusional ideas.

    The patient will be assessed using the Peter's Delusions Inventory - 21 items (PDI-21) before intervention, 3 months (more or less 15 days) after and 6 months (more or less 15 days) after the end of the intervention. Each item is scored on a scale of 1 to 4.The overall score ranges from 21 to 84 points.The higher the score, the greater the propensity for delusional ideas.

    Time frame: From enrollment until last assessment : 1 year

  5. Measure the impact of the collaborative therapeutic game "The Ocean of possibilities" on patients' capacity for mentalization.

    The patient will be assessed using the Mentalization Scale (Ment-S) before intervention, 3 months (more or less 15 days) after and 6 months (more or less 15 days) after the end of the intervention. Each item is scored on a scale of 1 to 5. The overall score ranges from 28 to 140 points.The higher the score, the more developed the person's capacity for mentalization.

    Time frame: From enrollment until last assessment : 1 year

Secondary outcomes

  1. Measure the impact of the collaborative therapeutic game "The Ocean of possibilities" on patients' social awareness.

    The patient will be assessed using the EASE scale (Examination of Anomalous Self-Experience. ) before intervention, 3 months (more or less 15 days) after and 6 months (more or less 15 days) after the end of the intervention.There are 50 questions, intended for parents. Each item is scored on a scale of 0 to 2. Overall score from 0 to 100 points. - The higher the score, the better the child masters the rules of social interaction and demonstrates an excellent ability to understand the intentions and emotions of others.

    Time frame: From enrollment until last assessment : 1 year

  2. Measure the anxiety impact of the collaborative therapeutic game "The Ocean of possibilities" on patients

    The patient will be assessed using the Revised Children Manifest Anxiety Scale (R-CMAS) questionnaire before intervention, 3 months (more or less 15 days) after and 6 months (more or less 15 days) after the end of the intervention. Each item is scored on a binary scale( 0 = No / 1 = Yes). The overall anxity score ranges from 0 to 28. A high score indicates that the child is suffering from significant generalized anxiety.

    Time frame: From enrollment until last assessment : 1 year

  3. Measure the impact of the collaborative therapeutic game "The Ocean of possibilities" on patients' social cognition

    The patient will be assessed using the Combined Stories Task (COST), before intervention, 3 months (more or less 15 days) after and 6 months (more or less 15 days) after the end of the intervention.The test includes 26 questions on mentalization, 6 questions on non-social reasoning, and 30 questions on control. Each item is scored on a scale of 0 to 1. For the QM score (Mentalization): The higher the score, the greater the ability to understand others' thoughts, hidden intentions, and emotions. For the QR score (Reasoning): The higher the score, the more intact the individual's logic and reasoning are when faced with physical or material situations. For the QC score (Control): The higher the score, the better the individual's attention, concentration, and working memory are maintained during the test.

    Time frame: From enrollment until last assessment : 1 year

  4. Measure the impact of the collaborative therapeutic game "The Ocean of possibilities" on patients' executive functions

    The patient will be assessed using the Behavior Rating Inventory of Executive Function (BRIEF) before intervention, 3 months (more or less 15 days) after and 6 months (more or less 15 days) after the end of the intervention. Each item is rated on a scale of 1 to 3 (1 = never, 2 = sometimes, 3 = often). The overall score ranges from 86 to 258. A high score indicates a greater degree of dysfunction or impairment in executive functions in daily life.

    Time frame: From enrollment until last assessment : 1 year

  5. Measure the impact of the collaborative therapeutic game "The Ocean of possibilities" on patients' cognitive flexibility

    The patient will be assessed using the "categorization" subtest of the Developmental Neuropsychological Assessment, Second Edition (NEPSY ii), before intervention, 3 months (more or less 15 days) after and 6 months (more or less 15 days) after the end of the intervention. The raw score is determined by the number of correct categories and the number of errors. It is then converted to a Standard Score (SS) using the conversion tables in the manual (NEPSYii). The standard score (SS) ranges from 1 to 19.A standard score between 8 and 12 means that cognitive flexibility is average for the patient's age.The lower the standard score(SS below 12), the lower the patient's cognitive flexibility. The higher the standard score (SS above 12), the better the cognitive flexibility.

    Time frame: From enrollment until last assessment : 1 year

  6. Measure the impact of the collaborative therapeutic game "The Ocean of possibilities" on patient's inhibitory abilities

    The patient will be assessed using the "Inhibition" subtest of the Developmental Neuropsychological Assessment, Second Edition (NEPSY ii), before intervention, 3 months (more or less 15 days) after and 6 months (more or less 15 days) after the end of the intervention. The raw score is determined by the number of errors and the time in seconds required. This score is converted to a Standard Score (SS) using the conversion tables in the manual (NEPSYii). The standard score ranges from 1 to 19. A standard score between 8 and 12 means that inhibitory abilities is average for the patient's age.The lower the standard score (below 12), the lower the patient's inhibitory abilities.The higher the standard score (above 12), the better the inhibitory abilities.

    Time frame: From enrollment until last assessment : 1 year

  7. Measure the impact of the collaborative therapeutic game "The Ocean of possibilities" on patient's verbal fluency

    The patient will be assessed using the "Word Generation" subtest of the Developmental Neuropsychological Assessment, Second Edition (NEPSY ii), before intervention, 3 months (more or less 15 days) after and 6 months (more or less 15 days) after the end of the intervention. The raw score is determined by the number of correct words. This score is converted to a Standard Score (SS) using the conversion tables in the manual (NEPSYii). The standard score ranges from 1 to 19. A standard score between 8 and 12 means that verbal fluency is average for the patient's age.The lower the standard score (below 12), the lower the patient's verbal fluency.The higher the standard score (above 12), the better the verbal fluency.

    Time frame: From enrollment until last assessment : 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Wykes T, Reeder C, Landau S, Everitt B, Knapp M, Patel A, Romeo R. Cognitive remediation therapy in schizophrenia: randomised controlled trial. Br J Psychiatry. 2007 May;190:421-7. doi: 10.1192/bjp.bp.106.026575. PubMed 17470957 ↗
  • Ueland T, Rund BR. A controlled randomized treatment study: the effects of a cognitive remediation program on adolescents with early onset psychosis. Acta Psychiatr Scand. 2004 Jan;109(1):70-4. doi: 10.1046/j.0001-690x.2003.00239.x. PubMed 14674961 ↗
  • Turner DT, van der Gaag M, Karyotaki E, Cuijpers P. Psychological interventions for psychosis: a meta-analysis of comparative outcome studies. Am J Psychiatry. 2014 May;171(5):523-38. doi: 10.1176/appi.ajp.2013.13081159. PubMed 24525715 ↗
  • Morrison AP, French P, Walford L, Lewis SW, Kilcommons A, Green J, Parker S, Bentall RP. Cognitive therapy for the prevention of psychosis in people at ultra-high risk: randomised controlled trial. Br J Psychiatry. 2004 Oct;185:291-7. doi: 10.1192/bjp.185.4.291. PubMed 15458988 ↗
  • Mignot, T., Bazille, M.-T., Bernardin, F., Schwan, R., & Laprevote, V. (2018). Le Centre de liaison et d'intervention précoce (CLIP) : L'exemple nancéien d'un partenariat avec la Maison des adolescents dans la prise en charge précoce des psychoses émergentes. Information psychiatrique, 94.
  • Medjkane, F., & Jardri, R. (2019). 15. Schizophrénies à début précoce et très précoce. In Les schizophrénies (p. 103-111). Lavoisier; Cairn.info. https://www.cairn.info/les-schizophrenies--9782257207395-p-103.htm
  • McGorry PD, Yung AR, Phillips LJ, Yuen HP, Francey S, Cosgrave EM, Germano D, Bravin J, McDonald T, Blair A, Adlard S, Jackson H. Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry. 2002 Oct;59(10):921-8. doi: 10.1001/archpsyc.59.10.921. PubMed 12365879 ↗
  • Marshall M, Rathbone J. Early intervention for psychosis. Cochrane Database Syst Rev. 2011 Jun 15;(6):CD004718. doi: 10.1002/14651858.CD004718.pub3. PubMed 21678345 ↗
  • Larøi, F., Van Der Linden, M., & Goëb, J.-L. (2009). Hallucinations et idées délirantes chez les enfants et adolescents : Mise en perspective avec les travaux réalisés chez l'adulte. Neuropsychiatrie de l'Enfance et de l'Adolescence, 57(1), 32-37. https://doi.org/10.1016/j.neurenf.2008.05.005
  • Kumra S, Charles Schulz S. Editorial: research progress in early-onset schizophrenia. Schizophr Bull. 2008 Jan;34(1):15-7. doi: 10.1093/schbul/sbm123. Epub 2007 Nov 28. PubMed 18048380 ↗
  • Khazaal Y, Favrod J, Azoulay S, Finot SC, Bernabotto M, Raffard S, Libbrecht J, Dieben K, Levoyer D, Pomini V. "Michael's Game," a card game for the treatment of psychotic symptoms. Patient Educ Couns. 2011 May;83(2):210-6. doi: 10.1016/j.pec.2010.05.017. Epub 2010 Jun 19. PubMed 20646892 ↗
  • Khazaal Y, Chatton A, Dieben K, Huguelet P, Boucherie M, Monney G, Lecardeur L, Salamin V, Bretel F, Azoulay S, Pesenti E, Krychowski R, Costa Prata A, Bartolomei J, Brazo P, Traian A, Charpeaud T, Murys E, Poupart F, Rouviere S, Zullino D, Parabiaghi A, Saoud M, Favrod J. Reducing Delusional Conviction through a Cognitive-Based Group Training Game: A Multicentre Randomized Controlled Trial. Front Psychiatry. 2015 Apr 28;6:66. doi: 10.3389/fpsyt.2015.00066. eCollection 2015. PubMed 25972817 ↗
  • Khazaal, Y. (2013). Michael's Game, un jeu d'entraînement au raisonnement par hypothèse : Étude randomisée contrôlée de son impact auprès de patients avec un trouble psychotique. European Psychiatry, 28(S2), 96-96. https://doi.org/10.1016/j.eurpsy.2013.09.257
  • Asarnow JR, Tompson MC, McGrath EP. Annotation: childhood-onset schizophrenia: clinical and treatment issues. J Child Psychol Psychiatry. 2004 Feb;45(2):180-94. doi: 10.1111/j.1469-7610.2004.00213.x. PubMed 14982235 ↗

Individual participant data

Plan to share: No — Data about study protocol and clinical information will be available on request from other researchers.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Mar 2025 (actual). Primary completion is estimated for Oct 2026, 19 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2026
First posted
Sep 21, 2026
StartActual
Mar 1, 2025
Primary completionEst.
Oct 1, 2026
CompletionEst.
Oct 1, 2028
Last update
Sep 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07831681
Lead sponsor
Hospital Center Guillaume Régnier
Responsible party
Sponsor
First posted
Sep 21, 2026
Start date
Mar 1, 2025
Primary completion
Oct 1, 2026 (estimated)
Completion
Oct 1, 2028 (estimated)
Last update
Sep 21, 2026

Study contacts

Valerie CHAUVEL
Contact
v.chauvel@ch-guillaumeregnier.fr
+332 99 33 39 18 ext. +33
Nathalie ALLETON
Contact
driri@ch-guillaumeregnier.fr
+332 22 51 41 21 ext. +33

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion